Wall Street's Best publication just released 1 hour ago
Bringing home the silver is William Velmer of S.A. Advisory. His pick was
Arrowhead Pharmaceuticals, Inc. (ARWR), which returned 81.0% to investors.
In his write-up, William noted, “ARWR therapies trigger RNA interference
mechanism to induce rapid, deep and durable knockdown of target genes.
Recently, AMGN & JNJ invested heavily with the potential of over $4 billion
in payments during milestones being reached. There are 100’s upon 100’s of
diseases that could be cured using ARWR’s methods of FC (functional cure)
that may change the world of medicine concerning how to cure diseases. We
believe because of all the milestones that will be met during 2019, that the share
price could easily double or triple.”New Top Pick
Predictive Technology Group, Inc. (PRED
3.9)
From S.A. Advisory
Predictive Technology Group, Inc. (PRED) aims
to revolutionize patient care through predictive
analytics, novel gene-based diagnostics and companion
therapeutics. These subs are focused on Endometriosis,
Scoliosis, degenerative disc disease and human cell and
tissue products.
At present PRED generates revenue by selling Human
Cells (STEM CELLS) & Tissue Products (HCT/P’s)
to clinics/ doctors. The run-rate is $40 million and
growing rapidly. Predictive is currently cash flow positive.
The company is near completion of its Endometriosis
test kit. The company recently announced collaboration
with Thermo Fisher (TMO~$25 billion in rev) in order
to focus on studying the genetic factors underlying
infertility in women. Global Endometriosis market is
expected to reach $2.3 billion within 5 years.
Predictive submitted its application on May 2nd 2019
to list on the NASDAQ. We anticipate listing any
day. Once listed we anticipate that the share price will
begin to appreciate rapidly because it allows all kinds of
funds to get involved with share ownership. We believe
Page 7 Wall Street’s Best Investments 819 July 10, 2019
New Top Pick continued
positive, new products to be released soon, world class
management, NASDAQ listing imminent, Wall Street
relations forming and additional joint ventures being
formed as well. Of course, there is always the issue of a
large short position that could cause a “squeeze” . In our
opinion, we could easily a $10-$15 share price by the
end of 2019. Strong buy at current levels.
William Velmer, S.A. Advisory, www.saadvisory.com
